How to Get Vyleesi (Bremelanotide) in Hawaii

What Is Vyleesi and Who Qualifies in Hawaii?

Vyleesi (bremelanotide) is an on-demand melanocortin-4 receptor agonist that the FDA approved in June 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women. It is not approved for postmenopausal HSDD, male sexual dysfunction, or arousal disorders unrelated to desire. The drug works by activating MC4R pathways in the central nervous system rather than targeting peripheral blood flow.

Clinical Trial Evidence

In the two key RECONNECT phase 3 trials (N=1,247 combined), bremelanotide 1.75 mg significantly increased desire and decreased distress compared with placebo over 24 weeks. The co-primary endpoints were the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score and the Female Sexual Function Index (FSFI) desire domain score. Women on bremelanotide reported a mean 0.35-point improvement in FSFI desire score above placebo and a -0.7-point reduction in FSDS-DAO Item 13 score compared with placebo (both P<0.01) 1.

Who Should Not Use It

Bremelanotide is contraindicated in women with uncontrolled hypertension or known cardiovascular disease, because it transiently raises blood pressure. The FDA label reports mean systolic BP increases of approximately 3 mmHg peaking about 2 to 3 hours after injection 2. Women using oral naltrexone are also excluded due to a pharmacodynamic interaction that reduces the efficacy of both drugs.

Telehealth Prescribing in Hawaii

Hawaii is one of the more telehealth-friendly states for prescribing schedule-unscheduled medications. Bremelanotide is not a controlled substance, which simplifies the prescribing pathway considerably. Under Hawaii Revised Statutes §453-1.3, physicians and APRNs may establish a provider-patient relationship via synchronous audio-video visit and prescribe non-controlled medications without requiring an in-person encounter.

How a Telehealth Visit Works

A typical telehealth consultation for Vyleesi in Hawaii follows a three-step workflow. First, the patient completes an intake questionnaire covering sexual health history, cardiovascular risk factors, current medications, and HSDD symptom duration. Second, the clinician conducts a live video visit lasting 15 to 30 minutes, during which they confirm HSDD diagnostic criteria (persistent low desire causing marked distress, present for at least 6 months, not attributable to another medical or psychiatric condition, relationship factors, or medication effects). Third, if clinically appropriate, the provider writes the prescription and transmits it electronically to a pharmacy licensed to dispense in Hawaii.

Choosing a Telehealth Provider

Not every national telehealth platform stocks Vyleesi in its formulary. When evaluating providers, confirm three things: (1) the prescriber holds an active Hawaii medical license, (2) the platform lists HSDD or female sexual health as a treatment category, and (3) the pharmacy network includes either a specialty pharmacy that ships to Hawaii or a 503A compounder licensed there. HealthRX clinicians are licensed in Hawaii and can prescribe bremelanotide via telehealth after a qualifying evaluation.

Which Providers Can Prescribe Vyleesi in Hawaii?

Three categories of clinicians hold independent or semi-independent prescriptive authority in Hawaii for non-controlled medications like bremelanotide.

Physicians (MD/DO)

Any physician with an active Hawaii Board of Medical Examiners license can prescribe Vyleesi. OB-GYNs, sexual medicine specialists, and primary care physicians are the most common prescribers. No additional DEA registration is needed because bremelanotide is unscheduled.

Advanced Practice Registered Nurses (APRNs)

Hawaii grants APRNs full practice authority under HRS §457-8.6. APRNs with prescriptive authority can independently prescribe Vyleesi without a collaborating physician agreement. This expands access in underserved areas, particularly on neighbor islands like Maui, Kauai, and Hawaii Island.

Physician Assistants (PAs)

PAs in Hawaii prescribe under a supervising physician relationship. A PA can prescribe Vyleesi as long as the medication falls within the scope of their supervisory agreement and the supervising physician has authorized prescribing for sexual health conditions.

Pre-Prescription Labs and Screening

The FDA label does not mandate specific laboratory tests before prescribing bremelanotide. Clinicians typically order targeted labs to rule out organic causes of low desire and to confirm cardiovascular safety.

Standard Pre-Prescribing Workup

A baseline blood pressure reading is the single most important screening measure, given the transient hypertensive effect. Most clinicians also order a basic metabolic panel, thyroid-stimulating hormone (TSH), and a hormone panel including estradiol, total testosterone, free testosterone, and DHEA-S. The hormone panel helps exclude other treatable causes of low libido such as hypothyroidism or hypoandrogenism 3.

The Endocrine Society's 2014 guidelines on androgen therapy in women recommend measuring testosterone before attributing desire complaints solely to HSDD, because low testosterone may warrant a separate treatment approach 4.

Monitoring After Initiation

Repeat blood pressure measurement at 4 to 6 weeks is reasonable. No routine lab monitoring is mandated. Clinicians should reassess HSDD symptom response at 8 weeks. If a patient reports no meaningful improvement after 8 uses, the FDA label suggests discontinuation.

Pharmacy Access and 503A Compounding in Hawaii

Getting the physical medication shipped to Hawaii introduces logistical considerations that mainland patients do not face.

Brand-Name Vyleesi

Brand Vyleesi is manufactured by Palatin Technologies and distributed as a single-dose autoinjector containing 1.75 mg of bremelanotide in 0.3 mL. The wholesale acquisition cost is approximately $950 for a carton of 4 autoinjectors. Not every retail pharmacy stocks it. Specialty pharmacies like Accredo, AllianceRx Walgreens Prime, and OptumRx Specialty can ship to Hawaii addresses, though transit times to the islands run 3 to 7 business days depending on the carrier.

503A Compounding Pharmacies

Hawaii permits licensed 503A compounding pharmacies to compound bremelanotide from bulk pharmaceutical-grade powder when a patient holds an individual prescription. Compounded bremelanotide is typically supplied as a multi-use vial with insulin syringes, at a substantially lower per-dose cost (often $50 to $150 per month compared with the brand price). The tradeoff: compounded formulations are not FDA-approved, are not subject to the same bioequivalence testing, and are not covered by manufacturer copay programs.

Shipping and Storage

Bremelanotide autoinjectors should be stored at 68°F to 77°F (20°C to 25°C). For shipments to Hawaii, confirm the pharmacy uses temperature-controlled packaging if ambient temperatures exceed this range, which is common in summer months. Compounded vials may require refrigeration depending on the formulation; the compounding pharmacy will specify handling instructions on the label.

Insurance Coverage and Prior Authorization in Hawaii

Coverage for Vyleesi varies sharply by payer type. Understanding your plan's formulary status before the prescriber writes the prescription saves time.

Hawaii Medicaid (Med-QUEST)

Hawaii Medicaid does not cover Vyleesi. Patients enrolled in Med-QUEST plans (AlohaCare, HMSA, Kaiser, UHC Community Plan) will need to pursue cash-pay, compounding, or manufacturer assistance options.

Commercial Insurance

Some commercial plans in Hawaii (HMSA PPO, Kaiser HMO, UnitedHealthcare) list Vyleesi on specialty tiers with prior authorization requirements. A 2022 analysis of commercial formulary coverage found that approximately 50% of large-group plans included bremelanotide with restrictions 5.

Prior Authorization Documentation

When a plan requires PA, the prescriber typically must submit:

• A confirmed HSDD diagnosis using DSM-5 criteria
• Documentation that the condition has persisted for 6 months or longer
• Evidence that non-pharmacologic interventions (psychotherapy, couples counseling) were attempted or considered
• Step therapy documentation showing trial and failure of flibanserin (Addyi), if the plan requires it
• Baseline blood pressure reading confirming no uncontrolled hypertension

Turnaround for PA decisions in Hawaii follows state insurance code timelines: standard requests within 15 calendar days, expedited (urgent) requests within 72 hours 6.

Manufacturer Savings Programs

AMAG Pharmaceuticals (which previously held U.S. Commercial rights) offered a copay card reducing out-of-pocket costs to as low as $0 for commercially insured patients. Check the current manufacturer's patient support portal for active programs, as these change with licensing transitions.

Cost Breakdown Without Insurance

For women paying entirely out of pocket, here is what to expect in Hawaii.

| Item | Estimated Cost | |---|---| | Telehealth consultation (initial) | $99 to $250 | | Lab panel (TSH, hormones, BMP) | $75 to $200 (cash-pay lab) | | Brand Vyleesi (4-pack autoinjector) | $900 to $1,050 | | Compounded bremelanotide (monthly supply) | $50 to $150 | | Shipping to Hawaii (specialty pharmacy) | $0 to $25 |

Compounding reduces the per-dose cost by roughly 75% to 90% compared to brand. For a woman using 4 to 6 doses per month, compounded bremelanotide through a 503A pharmacy is the most cost-effective route when insurance does not cover the brand.

Step-by-Step: Getting Vyleesi in Hawaii

This is the exact sequence from decision to first dose.

Step 1: Schedule a consultation. Book a telehealth or in-person visit with a licensed Hawaii prescriber who treats HSDD. Gather your medication list, blood pressure history, and any prior sexual health treatment records.

Step 2: Complete screening labs. If your clinician orders labs, use a Hawaii-based lab (Quest Diagnostics and Clinical Labs of Hawaii both operate on Oahu; neighbor island patients can use local draw sites or mobile phlebotomy). Results typically return within 2 to 3 business days.

Step 3: Receive your prescription. If you meet diagnostic criteria and have no contraindications, the prescriber sends the prescription to your chosen pharmacy electronically.

Step 4: Pharmacy processing. A specialty pharmacy or 503A compounder fills the order. Brand Vyleesi ships in 3 to 7 days to Hawaii. Compounded formulations may ship in 5 to 10 days depending on the pharmacy's compounding queue.

Step 5: Self-injection training. The autoinjector is designed for self-administration in the abdomen or thigh. Your provider or pharmacist should walk you through the injection technique, either in person or via a follow-up telehealth session. The injection is subcutaneous, using a 27-gauge needle for compounded vials.

Step 6: Administer 45 minutes before activity. Inject one dose at least 45 minutes before anticipated sexual activity. Do not exceed one dose in 24 hours or 8 doses in a calendar month.

Transferring a Prescription to Hawaii

If you already have a Vyleesi prescription from a mainland provider, transferring it to a Hawaii pharmacy is straightforward for non-controlled medications. Your current pharmacy can transfer the prescription to any Hawaii-licensed pharmacy upon request. The receiving pharmacist will verify the prescription's validity and the prescriber's license.

Interstate Telehealth Prescriptions

A prescription written by a provider in another state is valid in Hawaii only if that provider holds an active Hawaii medical license or the prescription was written during a period when the provider had temporary practice authority in Hawaii. If your mainland provider is not Hawaii-licensed, you will need a new consultation with a Hawaii-licensed clinician.

Neighbor Island Considerations

Access to sexual health specialists is concentrated on Oahu. Women on Maui, Kauai, Molokai, Lanai, and Hawaii Island face additional barriers.

Telehealth erases the geographic gap for the consultation itself. Pharmacy access, however, may require mail-order. There are no specialty pharmacies on most neighbor islands. The typical solution: a mainland or Oahu-based specialty pharmacy or 503A compounder ships directly to the patient's address.

The RECONNECT trials enrolled women across 110 U.S. Sites, but none were located in Hawaii 1. This means local clinical experience with bremelanotide is more limited than on the mainland, making telehealth access to experienced HSDD clinicians especially valuable for Hawaii residents.

Dr. Sheryl Kingsberg, a lead RECONNECT investigator, noted: "Bremelanotide offers an on-demand mechanism that fits into women's lives differently than a daily pill. The ability to use it only when desired removes the burden of daily medication adherence" 1.

The International Society for the Study of Women's Sexual Health (ISSWSH) process-of-care guidelines recommend that clinicians screen for HSDD proactively, because fewer than 20% of affected women voluntarily raise the concern during medical visits 7.

Safety and Side Effects to Discuss With Your Provider

The most common adverse reactions in clinical trials were nausea (40% of patients in RECONNECT), flushing (20%), injection site reactions (13%), and headache (11%) 2. Nausea was the primary reason for discontinuation, occurring in about 7% of treated patients.

A post-hoc analysis of RECONNECT data found that nausea severity typically decreased with repeated dosing 8. Women who continued past the first 4 doses reported substantially less nausea by month 2.

Focal hyperpigmentation of the face, gums, or breasts occurred in about 1% of patients and was generally reversible after discontinuation, though resolution could take months 2. The pigmentation effect is consistent with bremelanotide's melanocortin activity.

Bremelanotide 1.75 mg subcutaneously produced a mean peak systolic blood pressure increase of 3 mmHg at 2 to 3 hours post-dose. This returned to baseline within 12 hours in normotensive women 2.